Publications by authors named "E Perez Persona"
Purpose: A random home visit search investigated the prevalence and predictors of Dry Eye (DE) symptoms in Brazil.
Methods: Through home visits to 420 urban and 180 rural residences in the countryside of Southeast Brazil, the Dry Eye Disease Short Questionnaire (DEDSQ) was applied to volunteers 40 years and older. The predictive value of the DEDSQ and the risk factors were investigated.
Article Synopsis
- Doctors are unsure about the best time to start treatment for patients with relapsed/refractory multiple myeloma (RRMM) after they start getting worse again.
- A study looked at two groups, one that started treatment early (when the disease started to show signs) and the other that waited until symptoms got worse.
- The group that waited showed better treatment results, lasting longer without the disease getting worse compared to the group that started treatment early.
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Leuk Lymphoma
November 2023
We evaluated the psychometric properties of the Spanish version of the European Organization for Research and Treatment of Multiple Myeloma (MM) specific quality-of-life (QoL) questionnaire module (QLQ-MY20) in relapsed/refractory MM (RRMM) patients. This was an observational, cross-sectional, multicenter study using EORTC QLQ-C30 and QLQ-MY20 in RRMM patients (ClinicalTrials.gov ID NCT03188536).
View Article and Find Full Text PDFAnti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles.
View Article and Find Full Text PDFIntroduction: The GAH (Geriatric Assessment in Hematology) scale is a psychometrically valid tool aimed at identifying older patients with hematological malignancies at higher risk of treatment-related toxicity. Our objective in this study was to determine the weights for each dimension of the GAH scale and the cut-off point to reliably predict treatment tolerability in this population, estimated by a weighted receiver operating characteristic (ROC) analysis and quantified by the area under the curve (AUC).
Material And Methods: The RETROGAH was a retrospective cohort study including 126 patients who had previously participated in the GAH study.